Qiagen (QGEN) Hisse Özeti
Qiagen N.V. dünya çapında biyolojik numuneleri moleküler içgörülere dönüştüren numuneden içgörüye çözümler sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 3/6 |
QGEN Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Qiagen N.V. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$42.95 |
| 52 Haftanın En Yüksek Seviyesi | US$57.82 |
| 52 Haftanın En Düşük Seviyesi | US$32.53 |
| Beta | 0.62 |
| 1 Aylık Değişim | 4.37% |
| 3 Aylık Değişim | 25.44% |
| 1 Yıllık Değişim | -16.13% |
| 3 Yıllık Değişim | -12.03% |
| 5 Yıllık Değişim | -28.69% |
| Halka arzdan bu yana değişim | 1,859.88% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Aug 07
QGEN: Post Pandemic Testing And Takeover Interest Will Shape Oncology And Diagnostics Outlook
Qiagen's analyst price target has been revised higher to $45.28 from $43.96 as analysts factor in updated Q2 commentary, mixed but generally higher Street targets in the $36 to $48 range, and modest adjustments to growth and profitability assumptions. Analyst Commentary Recent Street research on Qiagen points to a mix of optimism and caution.
Anlatı Güncellemesi • Jul 23
QGEN: Takeover Interest Will Drive Reassessment Of Core Life Science Franchise
Qiagen's updated analyst price target has moved lower from about $55.91 to $49.47, reflecting mixed Street research. Several firms trimmed targets on QuantiFERON uncertainty, while others maintained Hold or moved to more positive stances, citing a solid life science franchise and potential growth inflection.Recent updates
Anlatı Güncellemesi • Aug 07
QGEN: Post Pandemic Testing And Takeover Interest Will Shape Oncology And Diagnostics Outlook
Qiagen's analyst price target has been revised higher to $45.28 from $43.96 as analysts factor in updated Q2 commentary, mixed but generally higher Street targets in the $36 to $48 range, and modest adjustments to growth and profitability assumptions. Analyst Commentary Recent Street research on Qiagen points to a mix of optimism and caution.Anlatı Güncellemesi • Jul 23
QGEN: Takeover Interest Will Drive Reassessment Of Core Life Science Franchise
Qiagen's updated analyst price target has moved lower from about $55.91 to $49.47, reflecting mixed Street research. Several firms trimmed targets on QuantiFERON uncertainty, while others maintained Hold or moved to more positive stances, citing a solid life science franchise and potential growth inflection.Seeking Alpha • Jul 12
Qiagen: New Launches Signal A Turnaround
Summary Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 09
QGEN: Reset Expectations And Product Pipeline Will Shape Medium Term Outlook
Analysts now place Qiagen's fair value at $36, down from $38. This reflects a reset in expectations around QuantiFERON growth and recent price target reductions, which offset more constructive views on the stock's longer term positioning and valuation.Anlatı Güncellemesi • Jun 25
QGEN: Expect Post Pandemic Testing Demand To Support Oncology And Diagnostics Expansion
Analysts have adjusted the fair value estimate for Qiagen slightly higher to $43.96 from $43.82, reflecting a modestly higher discount rate, alongside mixed recent price target moves that highlight both concerns over growth in areas like QuantiFERON and renewed interest in the stock as a potential structural beneficiary of post pandemic demand trends. Analyst Commentary Recent Street research on Qiagen reflects a split view, with some bullish analysts pointing to potential growth opportunities and valuation support, while more cautious analysts focus on execution risks and reduced expectations in key product areas.Analiz Makalesi • Jun 21
Qiagen (QGEN) Stock Could Be 15.7% Undervalued After QIAcuity Expansion
Qiagen (NYSE:QGEN) is in focus after announcing new additions to its QIAcuity digital PCR ecosystem, including expanded gene expression tools, higher multiplexing and upgraded software and automation for high throughput labs. See our latest analysis for Qiagen. The QIAcuity update comes as Qiagen’s share price has shown mixed momentum, with a 1-month share price return of 5.06%, a year-to-date share price return that is down 22.32%, and a 5-year total shareholder return that is down 23.67%...Anlatı Güncellemesi • Jun 06
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostics Expansion Beyond Current Headwinds
Qiagen's updated analyst price target has been reduced by about $9.70. This reflects analysts' lower growth and profitability assumptions after recent cuts across the Street tied to softer QuantiFERON trends and a rebased full year outlook.Yeni Anlatı • May 15
Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects
Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?Yeni Anlatı • Apr 30
Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact
Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Apr 29
QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion
Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.Anlatı Güncellemesi • Apr 10
QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns
Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.Anlatı Güncellemesi • Mar 27
QGEN: Possible Sale Prospects Are Expected To Drive Future Returns
The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.Anlatı Güncellemesi • Mar 12
QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns
The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.Anlatı Güncellemesi • Feb 25
QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside
Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.Anlatı Güncellemesi • Feb 11
QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks
Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.Anlatı Güncellemesi • Jan 28
QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition
Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.Anlatı Güncellemesi • Jan 08
QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions
Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).Analiz Makalesi • Jan 07
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued
Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...Anlatı Güncellemesi • Dec 14
QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead
Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.Anlatı Güncellemesi • Nov 29
QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms
Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.Anlatı Güncellemesi • Nov 15
QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside
Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.Analiz Makalesi • Nov 08
Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...Anlatı Güncellemesi • Oct 31
QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery
Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.Anlatı Güncellemesi • Oct 17
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.Anlatı Güncellemesi • Oct 03
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.Anlatı Güncellemesi • Sep 04
Syndromic Diagnostics And Automation Will Shape Future Healthcare
Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.Analiz Makalesi • Sep 02
Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality
Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...Hissedar Getirileri
| QGEN | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | -2.1% | 0.2% | 0.6% |
| 1Y | -16.1% | 18.6% | 20.1% |
Getiri vs. Endüstri: QGEN geçen yıl % 18.6 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: QGEN geçen yıl % 20.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| QGEN volatility | |
|---|---|
| QGEN Average Weekly Movement | 4.7% |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: QGEN son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: QGEN 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1984 | 5,500 | Thierry Bernard | www.qiagen.com |
Qiagen N.V. dünya çapında biyolojik numuneleri moleküler içgörülere dönüştüren numuneden içgörüye çözümler sunmaktadır. Şirket, numune materyalleri için nükleik asit stabilizasyon ve saflaştırma kitleri, genotipleme, gen ekspresyonu ve viral ve bakteriyel analiz için manuel ve otomatik işlemlerin yanı sıra silika membranlar ve manyetik boncuk teknolojileri gibi numune teknolojisi sarf malzemeleri; nükleik asitlerin saflaştırılması için kitler ve bileşenler dahil olmak üzere ikincil numune teknolojisi sarf malzemeleri ve nükleik asit saflaştırma, kalite kontrol ve aksesuarları için cihazlar sunmaktadır. Ayrıca, TB testi için interferon-gama salınım tahlili ve nakil sonrası test ve viral yük izleme için tahliller gibi bağışıklık yanıtı sarf malzemeleri; doğum öncesi test ve cinsel yolla bulaşan hastalıkların ve HPV'nin tespiti için tahliller dahil olmak üzere onkoloji ve cinsel sağlık ve üreme sağlığı sarf malzemeleri; genomik varyantların analizi için tahliller; ve teşhisi zor sendromların tek adımlı moleküler analizi ve entegre PCR testi dahil olmak üzere numuneden içgörüye araçlar sağlar.
Qiagen N.V. Temel Bilgiler Özeti
| QGEN temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$8.88b |
| Kazançlar(TTM) | US$409.32m |
| Gelir(TTM) | US$2.10b |
21.7x
F/K Oranı4.2x
P/S OranıQGEN aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| QGEN gelir tablosu (TTM) | |
|---|---|
| Gelir | US$2.10b |
| Gelir Maliyeti | US$706.05m |
| Brüt Kâr | US$1.39b |
| Diğer Giderler | US$985.00m |
| Kazançlar | US$409.32m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 1.98 |
| Brüt Marj | 66.38% |
| Net Kâr Marjı | 19.49% |
| Borç/Özkaynak Oranı | 49.3% |
QGEN uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
6.1%
Mevcut Temettü Verimi18%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/17 16:27 |
| Gün Sonu Hisse Fiyatı | 2026/08/14 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Qiagen N.V. 42 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Robert Bamberger | Baird |
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |